Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPHR HIT: Hypertonic Saline Dextran for Head Injury
NCT01642524Phase 3Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Apr 2004
- Primary completion
- Jan 2006
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of hypertonic saline + dextran-70 in traumatic brain injury (TBI) (2 arms), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: 30 day survival. Started Apr 2004; status: completed.
02
Drugs
hypertonic saline + dextran-70
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT01642524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01642524.